By
Background/Purpose: Induction regimens using either cyclophosphamide (CYC) or rituximab (RTX) have been shown to have similar efficacy and similar rates of adverse events in randomized trials of patients with a mean age of 54 yrs. Little is known about outcomes among older patients with ANCA-associated glomerulonephritis (ANCA GN) receiving such therapies. This study aimed to compare these outcomes in elderly ANCA GN on the basis of induction therapy regimen (CYC vs RTX).
Methods: Patients, ages 60 and above, diagnosed with ANCA GN clinically and histologically from 2004 to 2018 were retrospectively identified. Baseline characteristics and outcomes across several clinical parameters were recorded and compared between groups using t-test, Mann-Whitney-U test and Fisher’s exact test for significance as appropriate.
Jason Liebowitz, MD, completed his fellowship in rheumatology at Johns Hopkins University, Baltimore, where he also earned his medical degree. He is currently in practice with Skylands Medical Group, N.J.